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negative symptoms. The results suggest that functioning and improvement in
functioning are more strongly correlated with negative than with positive and
other symptom factors.
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OBJECTIVES: To examine the association of antidepressant-related weight gain
with degree of enjoyment and satisfaction from general daily activities, medication
and overall quality of life.METHODS: Employed individuals (18 years of age) with
depression (excluding bipolar disorder) completed a web-based computer-gener-
ated 25-minute survey (population identified by Harris Interactive). Weight gain
was measured using the Toronto Side Effects Scale which measures medication-
related side effects in the two weeks preceding the survey, and analyzed as a
4-level ordinal variable (none, 2lbs, 4lbs, 7lbs). Degree of enjoyment and
satisfaction related to general activities, satisfaction with current medication, and
overall quality of life were measured using a 5-point ordinal scale (1very poor;
5very good) employing the Quality of Life Enjoyment and Satisfaction Question-
naire – Short Form (QLESQ-SF). A summary “percent-of-max” score was calculated
for general activity items, and transformed to a 5-level ordinal variable using cut-
points of 20, 40, 60 and 80% (20% represented least overall enjoyment/satisfac-
tion) . Gender stratified cumulative logit models were used to estimate the effect of
weight gain on QLESQ-SF measures.RESULTS:Of the 1,521 survey respondents, 872
(57%) reported current antidepressant use (60.6% female, mean age 49.9  13.5
years). Compared to females with no weight gain, the odds of having lower enjoy-
ment/satisfaction were greater for females who experienced any weight gain:
2lbs (odds ratio [OR]2.22; p0.0001),4lbs (OR2.27; p0.004) and7lbs
(OR12.50; p0.0001). Among males lower QLESQ score was associated only with
the 7lbs category (OR5.26; p0.0004). Satisfaction with medication was in-
versely associated with weight gain for females; 2lbs (OR1.49; p0.051),
4lbs (OR2.33; p0.002) and 7lbs (OR8.33; p0.0001) and males; 7lbs
(OR2.78; p0.031). CONCLUSIONS: These data suggest that antidepressant-re-
lated weight gain may have strong associations with patient perceptions of dimin-
ished enjoyment and satisfaction in general daily activities and with current med-
ication, which may affect medication adherence.
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OBJECTIVES: The goal of this research was to compare the effect of donepezil oral
standard tablets (OST) versus donepezil oral disintegrating tablets (ODT) on stress
and objective burden in caregivers of de novo patients with dementia of AD in
routine medical practice. METHODS: A 6-month, prospective, observational study
enrolled naïve patients with possible/probable AD according to DSM-IV/NINCDS-
ADRDA criteria. Comparison on caregiver stress and objective burden was carried-
out between donepezil formulations of OST and ODT for a 6 month period. The
self-administered ZARIT scale and daily hours devoted to the care of patients on
basic and instrumental activities of daily-living (BADL, IADL), behaviour supervi-
sion and nursing home institutionalization were computed. RESULTS: 547 naïve
and de novo AD patients were analyzed: 123 (22.5%) received OST and 424 (77.5%)
ODT, at 7.1 (2.5) and 7.1 (2.6) mg/day, respectively. No significant differences were
observed in age, sex distribution, schooling, educational training, or relationship
with main caregiver between groups. Baseline clinical characteristics (comorbidi-
ties, symptoms of dementia duration, MMSE scoring) were homogeneous between
groups and remained unchanged during the study; Adjusted ZARIT scoring was
reduced significantly in ODT group by -1.1 point (p0.001) but this was not statis-
tically higher than the reduction observed in OST cohort; -0.5 (p0.527 between
groups comparison). Daily hours of care on BADL and IADL were not statistically
different between cohorts and remained unchanged during the study. Also, aver-
age number of hours/day on behaviour supervision or general supervision and the
percentage of caregivers having to quit their jobs were similar. CONCLUSIONS:
Findings of this study show that both subjective and objective burden of caregivers
of de novo patients with AD treated with donepezil remain stables during the
6-month period of the study, and it is unrelated with type of formulation given to
patients.
PMH59
EMPLOYMENT STATUS AND SELF REPORTED QUALITY OF LIFE IN CHINESE
PATIENTS RECEIVING TREATMENT FOR MAJOR DEPRESSIVE DISORDER
Xue HB1, Wu SH1, Brnabic AJ2, Novick D3, Kadziola Z2, Granger RE2, Montgomery W4
1Development Centre of Excellence Asia-Pacific, Lilly Suzhou Pharmaceutical Co Ltd, Shanghai
Branch, Shanghai, China, 2Development Centre of Excellence Asia-Pacific, Eli Lilly Australia Pty
Ltd, Macquarie Park, Australia, 3Eli Lilly and Co, Windlesham, Surrey, UK, 4Eli Lilly Australia
Pty Ltd, West Ryde, Australia
OBJECTIVES: Patients with major depressive disorder (MDD) frequently report
lower quality of life (QoL) and increased disability compared with the general pop-
ulation. This post hoc analysis describes the association between QoL, painful
physical symptoms (PPS), depressive symptoms and employment status in a Chi-
nese MDD patient cohort. METHODS: Chinese MDD patients (299) from a prospec-
tive observational study of six East Asian countries/regions were compared at base-
line and after 3 months of naturalistic treatment on QoL (EuroQoL Questionnaire-5
Dimensions [EQ-5D] utility score), PPS (Somatic Symptom Inventory [SSI]), depres-
sion (17-item Hamilton Depression Rating Scale [HAMD17]) and employment sta-
tus measures. Patients were classified as PPS positive or negative (PPS, PPS-; SSI
mean score 2 or 2 respectively). Effect sizes (ES) were calculated using Cohen’s
d. RESULTS: Patients who were employed at baseline reported higher QoL (EQ-5D:
0.60 vs. 0.42; ES 0.7) and were less severely ill (HAMD17 total score: 22.7 vs. 26.0; ES
-0.7) than those who were unemployed. Few transitions in employment status
were observed during the study. Self-reported QoL was low (EQ-5D: mean 0.52) at
baseline and improved substantially after 3 months (EQ-5D: 0.89). PPS patients
were more severely ill (HAMD17: 25.4 vs. 23.3; ES 0.4) and had a lower QoL (EQ-5D:
0.41 vs. 0.58; ES -0.6) at baseline than PPS- patients. The higher illness severity
(HAMD17: 7.0 vs. 4.6; ES 0.4) and lower QoL (EQ-5D: 0.83 vs. 0.92; ES -0.6) of PPS
patients persisted after 3 months. CONCLUSIONS: Employed patients reported a
higher QoL and a lower symptomatic burden than unemployed patients. Patients
with a low QoL were more likely to be unemployed. The QoL of Chinese MDD
patients improved over 3 months of naturalistic treatment. The presence of PPS
was associated with higher illness severity and lower QoL at baseline and after 3
months.
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OBJECTIVES: Health-related Quality of Life (HRQoL) has become both a target of
intervention and a crucial outcome in evaluating treatment of alcohol dependence.
Little has been studied on the factors associated with HRQoL before alcohol depen-
dence treatment. We explored the association between HRQoL and several risk
factors including level of alcohol consumption. METHODS: We used data from
CONTROL, an observational cohort study on 143 alcohol dependent patients from
Lausanne hospital, Switzerland, followed for 12 months. Average daily alcohol
consumption was collected every month and categorised according to the World
Health Organisation’s risk levels (WRL) classification: high, medium, low or absti-
nent. Other measures were collected every three months: HRQoL (SF-36), Beck
inventory depression score (BDI) and sociodemographic characteristics. The mean
score for each dimension and for the Physical and Mental Component Summary
Score (PCS and MCS) were calculated at baseline and at 12-months. Correlates of
MCS and PCS were identified using Pearson correlation coefficients and factors
associated with change from baseline to 12-months were identified using linear
mixed models. RESULTS: At baseline, except for physical functioning, all average
SF-36 scores were below those in the general population. The most impaired scores
were those with the heavier contribution to MCS. MCS was significantly correlated
with BDI, WRL and age. Compared to abstinent patients, difference in MCS scores
was significantly lower in patients with medium (difference-12.9; p0.005) or
high risk (difference-14.8; p0.0001) levels whereas no significant difference was
observed between abstinent and low risk patients (difference-7.3; N.S.). Change in
MCS from baseline to 12-months was associated with BDI and WRL. No significant
association was found with PCS. CONCLUSIONS: HRQol is significantly in alcohol-
dependent patients. The level of alcohol consumption and depression appeared as
important drivers of HRQoL related to mental health.
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OBJECTIVES: To describe treatment characteristics among children with Attention
Deficit/Hyperactivity Disorder (ADHD) using atomoxetine in two European
countries. METHODS: Medical charts of patients aged 6-17 with 1 diagnosis of
ADHD between 1/2004-6/2007 were reviewed by physicians from 6 European coun-
tries. All patients had 2 years of follow-up data and received pharmacological or
behavioral therapy post-diagnosis, and were not enrolled in a clinical trial. This
analysis focused on two countries with the largest samples of Strattera® (atomox-
etine HCL) users: UK (UK) and Italy (IT). Outcomes presented include descriptive
statistics (means, rates, percentages) describing treatment: patterns, response and
satisfaction. RESULTS: 94 patients met inclusion criteria (UK [n51], IT [n43]).
Patients were predominantly male 80.4% (UK) and 76.7% (IT), Caucasian, 88.2% and
95.3% and mean (SD) age at diagnosis was 9.5(2.6) and 9.0(2.9). Most patients were
diagnosed via the Connors (76.5%) (UK) or DSM-IV (51.1%; IT) criteria. A majority of
patients presented as combined type ADHD (hyperactive/impulsive and inatten-
tive symptoms) (UK 74% and IT 62%). Between 63% to 76% of all patients indi-
cated 8 impairment for impulsivity and hyperactivity (scale from 0 “no impair-
ment” to 10 “high level impairment”). 76.5% (UK) and 55.8% (IT) of patients received
two or more ADHD treatments and 42.1% and 20.5% received a methylphenidate
product; 37.3% and 32.6% of physicians in the UK and IT, respectively, indicated
that these patients had a “poor” or “very poor” response to methylphenidate. 64.9%
of patients were currently prescribed atomoxetine vs. 35.1% previously prescribed.
23.0% of physicians of current patients indicated that they were “neither satisfied
nor dissatisfied,” “moderately dissatisfied,” or “very dissatisfied” with current ato-
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